BACKGROUND: The recently discovered indoleamine 2,3-dioxygenase-2 (IDO2) gene has 2 functional polymorphisms that abolish its enzymatic activity. We hypothesize that expression of the IDO2 enzyme in primary pancreatic ductal adenocarcinomas (PDA) can help cancer cells evade immune detection. STUDY DESIGN: Because the IDO2 enzyme might be the preferential target of d-1-methyl-tryptophan, a clinical lead inhibitor of IDO currently being evaluated in phase I trials, we sequenced IDO2 in 36 pancreatic specimens and evaluated its expression. RESULTS: We found that 58% (21 of 36) of cases were heterozygous for the R248W polymorphism; 28% (10 of 36) were homozygous wild-type; and only 14% (5 of 36) were homozygous for the functionally inactive polymorphism. As for the Y359STOP polymorphism, we found that 27% (10 of 36) of cases were heterozygous, 62% (22 of 36) were homozygous wild-type, and only 11% (4 of 36) were homozygous for this functionally inactive allele. Ruling out the possibility of compound polymorphic variants, we estimated 75% of our resected patient cohort had an active IDO2 enzyme, with a conservative estimate that 58% of the patients had at least 1 functional allele. IDO2 was expressed in PDA tissue from each genetically polymorphic subgroup. We also detected IDO2 protein expression in the genetically distinct pancreatic cancer cell lines after exposure with interferon-gamma. CONCLUSIONS: This is the first study to report IDO2 expression in PDA and related cancers indicating that IDO2 genetic polymorphisms do not negate interferon-gamma-inducible protein expression. Taken together, our data strongly suggest that the clinical lead compound d-1-methyl-tryptophan might be useful in treatment of PDA.
BACKGROUND: The recently discovered indoleamine 2,3-dioxygenase-2 (IDO2) gene has 2 functional polymorphisms that abolish its enzymatic activity. We hypothesize that expression of the IDO2 enzyme in primary pancreatic ductal adenocarcinomas (PDA) can help cancer cells evade immune detection. STUDY DESIGN: Because the IDO2 enzyme might be the preferential target of d-1-methyl-tryptophan, a clinical lead inhibitor of IDO currently being evaluated in phase I trials, we sequenced IDO2 in 36 pancreatic specimens and evaluated its expression. RESULTS: We found that 58% (21 of 36) of cases were heterozygous for the R248W polymorphism; 28% (10 of 36) were homozygous wild-type; and only 14% (5 of 36) were homozygous for the functionally inactive polymorphism. As for the Y359STOP polymorphism, we found that 27% (10 of 36) of cases were heterozygous, 62% (22 of 36) were homozygous wild-type, and only 11% (4 of 36) were homozygous for this functionally inactive allele. Ruling out the possibility of compound polymorphic variants, we estimated 75% of our resected patient cohort had an active IDO2 enzyme, with a conservative estimate that 58% of the patients had at least 1 functional allele. IDO2 was expressed in PDA tissue from each genetically polymorphic subgroup. We also detected IDO2 protein expression in the genetically distinct pancreatic cancer cell lines after exposure with interferon-gamma. CONCLUSIONS: This is the first study to report IDO2 expression in PDA and related cancers indicating that IDO2 genetic polymorphisms do not negate interferon-gamma-inducible protein expression. Taken together, our data strongly suggest that the clinical lead compound d-1-methyl-tryptophan might be useful in treatment of PDA.
Authors: Alexander J Muller; James B DuHadaway; P Scott Donover; Erika Sutanto-Ward; George C Prendergast Journal: Nat Med Date: 2005-02-13 Impact factor: 53.440
Authors: Eric S Calhoun; Tomas Hucl; Eike Gallmeier; Kristen M West; Dan E Arking; Anirban Maitra; Christine A Iacobuzio-Donahue; Aravinda Chakravarti; Ralph H Hruban; Scott E Kern Journal: Cancer Res Date: 2006-08-15 Impact factor: 12.701
Authors: Francesca Fallarino; Ursula Grohmann; Sylvaine You; Barbara C McGrath; Douglas R Cavener; Carmine Vacca; Ciriana Orabona; Roberta Bianchi; Maria L Belladonna; Claudia Volpi; Pere Santamaria; Maria C Fioretti; Paolo Puccetti Journal: J Immunol Date: 2006-06-01 Impact factor: 5.422
Authors: De-Yan Hou; Alexander J Muller; Madhav D Sharma; James DuHadaway; Tinku Banerjee; Maribeth Johnson; Andrew L Mellor; George C Prendergast; David H Munn Journal: Cancer Res Date: 2007-01-15 Impact factor: 12.701
Authors: Gerald Brandacher; Alexander Perathoner; Ruth Ladurner; Stefan Schneeberger; Peter Obrist; Christiana Winkler; Ernst R Werner; Gabriele Werner-Felmayer; Helmut G Weiss; Georg Göbel; Raimund Margreiter; Alfred Königsrainer; Dietmar Fuchs; Albert Amberger Journal: Clin Cancer Res Date: 2006-02-15 Impact factor: 12.531
Authors: Alexander J Muller; James B DuHadaway; Mee Young Chang; Arivudinambi Ramalingam; Erika Sutanto-Ward; Janette Boulden; Alejandro P Soler; Laura Mandik-Nayak; Susan K Gilmour; George C Prendergast Journal: Cancer Immunol Immunother Date: 2010-07-17 Impact factor: 6.968
Authors: Richard Metz; Courtney Smith; James B DuHadaway; Phillip Chandler; Babak Baban; Lauren M F Merlo; Elizabeth Pigott; Martin P Keough; Sonja Rust; Andrew L Mellor; Laura Mandik-Nayak; Alexander J Muller; George C Prendergast Journal: Int Immunol Date: 2014-01-08 Impact factor: 4.823
Authors: Maria Winters; James B DuHadaway; Khoa N Pham; Ariel Lewis-Ballester; Shorouk Badir; Jenny Wai; Eesha Sheikh; Syun-Ru Yeh; George C Prendergast; Alexander J Muller; William P Malachowski Journal: Eur J Med Chem Date: 2018-11-14 Impact factor: 6.514
Authors: Isadora C Botwinick; Lisa Pursell; Gary Yu; Tom Cooper; J John Mann; John A Chabot Journal: HPB (Oxford) Date: 2014-01-28 Impact factor: 3.647